NCT04412577 - A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

June 30, 2022

Conditions

Relapsed/Refractory Hematological Malignancies

Interventions

DRUG

TQB3473

TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.

Trial Locations (2)

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

RECRUITING

Henan Cancer Hospital, Zhengzhou